Skip to Content

We invite you to try out our new beta eCFR site at We’ve made big changes to make the eCFR easier to use. Be sure to leave feedback using the 'Feedback' button on the bottom right of each page!


A Conversation About Cancer Drug Development With Cancer Patient Advocates

Document Details

Information about this document as published in the Federal Register.

Document Statistics
Document page views are updated periodically throughout the day and are cumulative counts for this document. Counts are subject to sampling, reprocessing and revision (up or down) throughout the day.
Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble


Food and Drug Administration, HHS.


Notice of meeting.

The Food and Drug Administration (FDA) is announcing the following meeting: A Conversation About Cancer Drug Development With Cancer Patient Advocates. The topics to be discussed are: Fast track, compassionate use, quality of life, the Patient Consultant Program, and other issues as they arise.

Date and Time: The meeting will be held on June 29, 2001, 2 p.m. to 4 p.m.

Location: The meeting will be held at the Westin Fairfax Hotel, Whitehall Room, 2100 Massachusetts Ave. NW., Washington, DC 20008, 202-293-2100.

Contacts: Patricia C. Delaney and JoAnn M. Minor, Office of Special Health Issues, Cancer Liaison Program, Office of International and Constituent Relations, Office of the Commissioner, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-4460, FAX: 301-443-4555, or e-mail: and

Registration: Send registration information (including name, title, firm name, address, telephone, fax number and/or e-mail address) to either contact person by June 22, 2001.

If you need special accommodations due to a disability, please contact Patricia C. Delaney or JoAnn M. Minor at least 7 days in advance.

Start Signature

Dated: June 8, 2001.

Margaret M. Dotzel,

Associate Commissioner for Policy.

End Signature End Preamble

[FR Doc. 01-14930 Filed 6-13-01; 8:45 am]